Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B Study Evaluating RO7082859 in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed Refractory Follicular Lymphoma (R/R FL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase 1B Study Evaluating RO7082859 in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed Refractory Follicular Lymphoma (R/R FL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RO 7082859 (Primary) ; Cyclophosphamide; Doxorubicin; Obinutuzumab; Prednisone; Prednisone; Rituximab; Tocilizumab; Vincristine
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 17 Oct 2019 Status changed from active, no longer recruiting to recruiting.
    • 11 Sep 2019 Status changed from recruiting to active, no longer recruiting.
    • 11 Jul 2019 Planned End Date changed from 17 Jun 2023 to 16 Dec 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top